JOHNSON & JOHNSON is 507.9x more valuable than Zenas BioPharma, Inc. by market capitalization ($573.98 B vs $1.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZBIO | JNJ |
|---|---|---|
| Market cap | $1.13 B | $573.98 B |
| US-listed rank | #2546 | #20 |
| Revenue (latest FY) | $10.00M | $94.19B |
| Net income (latest FY) | -$377.74M | $26.80B |
| Net margin | -3777.4% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 166 | 984 |
JOHNSON & JOHNSON is 507.9x more valuable than Zenas BioPharma, Inc. by market capitalization ($573.98 B vs $1.13 B).
In their latest fiscal years, Zenas BioPharma, Inc. reported $10.00M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Zenas BioPharma, Inc. and JOHNSON & JOHNSON, or browse the full rankings.